Protocol Ledger

NCT04695652 · Phase II · COMPLETED

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult

Interventional Phase II clinical trial protocol NCT04695652 sponsored by Medigen Vaccine Biologics in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-30 Enrollment: 3,854 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04695652
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3,854 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04695652
Protocol FieldVerified Registry Value
NCT IdentifierNCT04695652
Consolidated Lead SponsorMedigen Vaccine Biologics
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment3,854 participants (ACTUAL)
Registered Start Date2020-12-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI